Abnormal placentation: modern views on etiology, pathogenesis and diagnosis
DOI: 10.32364/2618-8430-2023-6-1-20-25
Yu.E. Dobrokhotova1, E.I. Borovkova1, I.A. Kulikov2, T.N. Belousova2, M.V. Burdenko1, D.S. Davydova1 , N.R. Manafova1
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2Vidnoe Perinatal Center, Vidnoe, Russian Federation
The increasing trend in surgical delivery (caesarean section) rates observed over the last several years results in a rise of abnormal placentation (AP) cases. In this context, timely diagnosis and correct routing of patients with abnormal placentation to level 3 specialized healthcare institutions will ensure the provision of quality medical care and thus to minimize maternal and infant mortality. The article presents modern views on the main risk factors and pathogenesis of AP, updated definitions of placenta adherenta, increta and percreta and the latest clinical and morphological classification. The authors highlight the advanced diagnostic criteria based on sonographic imaging, Doppler color flow mapping, an important method required for making diagnosis. They also specify cases where MRI techniques could be more informative than ultrasound methods and describe MRI findings that suggest abnormal placentation. Major strategies for providing effective healthcare ar e considered, including organ preserving surgical procedures, hemostasis (endovascular occlusion or embolization) and replacement of blood loss (reinfusion or hemotransfusion), etc. to reduce the prevalence of unfavorable obstetric and perinatal outcomes.
Keywords: placentation, uterine scar, caesarean section, placenta adherenta, placenta increta, placenta percreta, hemorrage.
For citation: Dobrokhotova Yu.E., Borovkova E.I., Kulikov I.A. et al. Abnormal placentation: modern views on etiology, pathogenesis and diagnosis. Russian Journal of Woman and Child Health. 2023;6(1):20–25 (in Russ.). DOI: 10.32364/2618-8430-2023-6-1-20-25.
About the authors:
Yuliya E. Dobrokhotova — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-7830-2290.
Ilyas A. Kulikov — C. Sc. (Med.), Head of the Obstetric Department of Pathologic Pregnancy, Vidnoe Perinatal Center; 17, Zavodskaya str., Vidnoe, 142700, Russian Federation; ORCID iD 0000-0002-2460-1623.
Tamara N. Belousova — C. Sc. (Med.), Chief Doctor, Vidnoe Perinatal Center; 17, Zavodskaya str., Vidnoe, 142700, Russian Federation; ORCID iD 0000-0003-3804-7691.
Ekaterina I. Borovkova — Dr. Sc. (Med.), professor of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0001-7140-262X.
Marina V. Burdenko — C. Sc. (Med.), associate professor of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-0304-4901.
Darya S. Davydova — resident of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-6598-9310.
Nasiyat R. Manafova — resident of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-3910-307X.
Contact information: Yuliya E. Dobrokhotova, e-mail: pr.dobrohotova@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 06.12.2022.
Revised 29.12.2022.
Accepted 30.01.2023.
2. Jauniaux E., Bunce C., Grønbeck L., Langhoff-Roos J. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(3):208–218. DOI: 10.1016/j.ajog.2019.01.233.
3. Jauniaux E., Chantraine F., Silver R.M. et al. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. Int J Gynaecol Obstet. 2018;140(3):265–273. DOI: 10.1002/ijgo.12407.
4. Jauniaux E., Hussein A.M., Elbarmelgy R.M. et al. Failure of placental detachment in accreta placentation is associated with excessive fibrinoid deposition at the utero-placental interface. Am J Obstet Gynecol. 2022;226(2):243.e1–243.e10. DOI: 10.1016/j.ajog.2021.08.026.
5. Jauniaux E., Hecht J.L., Elbarmelgy R.A. et al. Searching for placenta percreta: a prospective cohort and systematic review of case reports. Am J Obstet Gynecol. 2022;226(6):837.e1–837.e13. DOI: 10.1016/j.ajog.2021.12.030.
6. Jauniaux E., Jurkovic D., Hussein A.M., Burton G.J. New insights into the etiopathology of placenta accreta spectrum. Am J Obstet Gynecol. 2022;227(3):384–391. DOI: 10.1016/j.ajog.2022.02.038.
7. Tantbirojn P., Crum C.P., Parast M.M. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta. 2008;29(7):639–645. DOI: 10.1016/j.placenta.2008.04.008.
8. Jauniaux E., Collins S., Burton G.J. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218(1):75–87. DOI: 10.1016/j.ajog.2017.05.067.
9. Silver R.M., Landon M.B., Rouse D.J. et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006;107(6):1226–1232. DOI: 10.1097/01.AOG.0000219750.79480.84.
10. Kohn J.R., Shamshirsaz A.A., Popek E. et al. Pregnancy after endometrial ablation: a systematic review. BJOG. 2018;125(1):43–53. DOI: 10.1111/1471-0528.14854.
11. Silver R.M., Fox K.A., Barton J.R. et al. Center of excellence for placenta accreta. Am J Obstet Gynecol. 2015;212(5):561–568. DOI: 10.1016/j.ajog.2014.11.018.
12. Baldwin H.J., Patterson J.A., Nippita T.A. et al. Antecedents of Abnormally Invasive Placenta in Primiparous Women: Risk Associated With Gynecologic Procedures. Obstet Gynecol. 2018;131(2):227–233. DOI: 10.1097/AOG.0000000000002434.
13. Salmanian B., Fox K.A., Arian S.E. et al. In vitro fertilization as an independent risk factor for placenta accreta spectrum. Am J Obstet Gynecol. 2020;223(4):568.e1–568.e5. DOI: 10.1016/j.ajog.2020.04.026.
14. Miller H.E., Leonard S.A., Fox K.A. et al. Placenta Accreta Spectrum Among Women With Twin Gestations. Obstet Gynecol. 2021;137(1):132–138. DOI: 10.1097/AOG.0000000000004204.
15. Kayem G., Seco A., Beucher G. et al. Clinical profiles of placenta accreta spectrum: the PACCRETA population-based study. BJOG. 2021;128(10):1646–1655. DOI: 10.1111/1471-0528.16647.
16. Hessami K., Salmanian B., Einerson B.D. et al. Clinical correlates of placenta accreta spectrum disorder depending on the presence or absence of placenta previa: a systematic review and meta-analysis. Obstet Gynecol. 2022;140(4):599–606. DOI: 10.1097/AOG.0000000000004923.
17. Carusi D.A., Fox K.A., Lyell D.J. et al. Placenta Accreta Spectrum Without Placenta Previa. Obstet Gynecol. 2020;136(3):458–465. DOI: 10.1097/AOG.0000000000003970.
18. Fitzpatrick K.E., Sellers S., Spark P. et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014;12(1):62–70; discussion 70–71. DOI: 10.1111/1471-0528.12405.
19. Bailit J.L., Grobman W.A., Rice M.M. et al. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125(3):683–689. DOI: 10.1097/AOG.0000000000000680.
20. Thurn L., Lindqvist P.G., Jakobsson M. et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016;123(8):1348–1355. DOI: 10.1111/1471-0528.13547.
21. Comstock C.H., Lee W., Vettraino I.M., Bronsteen R.A. The early sonographic appearance of placenta accreta. J Ultrasound Med. 2003;22(1):19–23; quiz 24–26. DOI: 10.7863/jum.2003.22.1.19.
22. Stirnemann J.J., Mousty E., Chalouhi G. et al. Screening for placenta accreta at 11–14 weeks of gestation. Am J Obstet Gynecol. 2011;205(6):547.e1–547.e6. DOI: 10.1016/j.ajog.2011.07.021.
23. Calí G., Timor-Tritsch I.E., Forlani F. et al. Value of first-trimester ultrasound in prediction of third-trimester sonographic stage of placenta accreta spectrum disorder and surgical outcome. Ultrasound Obstet Gynecol. 2020;55(4):450–459. DOI: 10.1002/uog.21939.
24. Happe S.K., Rac M.W.F., Moschos E. et al. Prospective First-Trimester Ultrasound Imaging of Low Implantation and Placenta Accreta Spectrum. J Ultrasound Med. 2020;39(10):1907–1915. DOI: 10.1002/jum.15295.
25. Rac M.W., Moschos E., Wells C.E. et al. Sonographic Findings of Morbidly Adherent Placenta in the First Trimester. J Ultrasound Med. 2016;35(2):263–269. DOI: 10.7863/ultra.15.03020.
26. Doulaveris G., Ryken K., Papathomas D. et al. Early prediction of placenta accreta spectrum in women with prior cesarean delivery using transvaginal ultrasound at 11 to 14 weeks. Am J Obstet Gynecol MFM. 2020;2(4):100183. DOI: 10.1016/j.ajogmf.2020.100183.
27. Comstock C.H. Antenatal diagnosis of placenta accreta: a review. Ultrasound Obstet Gynecol. 2005;26(1):89–96. DOI: 10.1002/uog.1926.
28. Pagani G., Cali G., Acharya G. et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018;97(1):25–37. DOI: 10.1111/aogs.13238.
29. Berkley E.M., Abuhamad A.Z. Prenatal diagnosis of placenta accreta: is sonography all we need? J Ultrasound Med. 2013;32(8):1345–1350. DOI: 10.7863/ultra.32.8.1345.
30. Comstock C.H., Bronsteen R.A. The antenatal diagnosis of placenta accreta. BJOG. 2014;12(2):171–181; discussion 181–182. DOI: 10.1111/1471-0528.12557.
31. Maldjian C., Adam R., Pelosi M. et al. MRI appearance of placenta percreta and placenta accreta. Magn Reson Imaging. 1999;17(7):965–971. DOI: 10.1016/s0730-725x(99)00035-1.
32. Jha P., Pōder L., Bourgioti C. et al. Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders. Eur Radiol. 2020;30(5):2604–2615. DOI: 10.1007/s00330-019-06617-7.
33. Bourgioti C., Zafeiropoulou K., Fotopoulos S. et al. MRI prognosticators for adverse maternal and neonatal clinical outcome in patients at high risk for placenta accreta spectrum (PAS) disorders. J Magn Reson Imaging. 2019;50(2):602–618. DOI: 10.1002/jmri.26592.
34. Kupferminc M.J., Tamura R.K., Wigton T.R. et al. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol. 1993;82(2):266–269. PMID: 7687756.
35. Shainker S.A., Silver R.M., Modest A.M. et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol. 2020;223(3):433.e1–433.e14. DOI: 10.1016/j.ajog.2020.03.019.
36. Washecka R., Behling A. Urologic complications of placenta percreta invading the urinary bladder: a case report and review of the literature. Hawaii Med J. 2002;61(4):66–69. PMID: 12050959.
37. Mehrabadi A., Hutcheon J.A., Liu S. et al. Contribution of placenta accreta to the incidence of postpartum hemorrhage and severe postpartum hemorrhage. Obstet Gynecol. 2015;125(4):814–821. DOI: 10.1097/AOG.0000000000000722.
38. Zelop C.M., Harlow B.L., Frigoletto F.D. Jr. et al. Emergency peripartum hysterectomy. Am J Obstet Gynecol. 1993;168(5):1443–1448. DOI: 10.1016/s0002-9378(11)90779-0.
39. Glaze S., Ekwalanga P., Roberts G. et al. Peripartum hysterectomy: 1999 to 2006. Obstet Gynecol. 2008;111(3):732–738. DOI: 10.1097/AOG.0b013e31816569f2.
40. Morlando M., Schwickert A., Stefanovic V. et al. Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: A multinational database study. Acta Obstet Gynecol Scand. 2021;100 Suppl 1:41–49. DOI: 10.1111/aogs.14120.
41. Warshak C.R., Ramos G.A., Eskander R. et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol. 2010;115(1):65–69. DOI: 10.1097/AOG.0b013e3181c4f12a.
42. Shamshirsaz A.A., Fox K.A., Salmanian B. et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol. 2015;212(2):218.e1–218.e9. DOI: 10.1016/j.ajog.2014.08.019.
43. Grosvenor A., Silver R., Porter T.F., Zempolich K. Optimal management of placenta accreta. Am J Obstet Gynecol. 2007;195:S82.
44. Van Beekhuizen H.J., Stefanovic V., Schwickert A. et al. A multicenter observational survey of management strategies in 442 pregnancies with suspected placenta accreta spectrum. Acta Obstet Gynecol Scand. 2021;100 Suppl 1(Suppl 1):12–20. DOI: 10.1111/aogs.14096.
45. Einerson B.D., Weiniger C.F. Placenta accreta spectrum disorder: updates on anesthetic and surgical management strategies. Int J Obstet Anesth. 2021;46:102975. DOI: 10.1016/j.ijoa.2021.102975.
46. Publications Committee, Society for Maternal-Fetal Medicine, Belfort M.A. Placenta accreta. Am J Obstet Gynecol. 2010;203(5):430–439. DOI: 10.1016/j.ajog.2010.09.013.
47. Eller A.G., Bennett M.A., Sharshiner M. et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol. 2011;117(2 Pt 1):331–337. DOI: 10.1097/AOG.0b013e3182051db2.
48. Bartels H.C., Rogers A.C., O'Brien D. et al. Association of Implementing a Multidisciplinary Team Approach in the Management of Morbidly Adherent Placenta With Maternal Morbidity and Mortality. Obstet Gynecol. 2018;132(5):1167–1176. DOI: 10.1097/AOG.0000000000002865.
49. Schwickert A., van Beekhuizen H.J., Bertholdt C. et al. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): A multinational database study. Acta Obstet Gynecol Scand. 2021;100 Suppl 1:29–40. DOI: 10.1111/aogs.14103.
50. Eller A.G., Porter T.F., Soisson P., Silver R.M. Optimal management strategies for placenta accreta. BJOG. 2009;116(5):648–654. DOI: 10.1111/j.1471-0528.2008.02037.x.
51. Tikkanen M., Paavonen J., Loukovaara M., Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. Acta Obstet Gynecol Scand. 2011;90(10):1140–1146. DOI: 10.1111/j.1600-0412.2011.01147.x.
52. Sadashivaiah J., Wilson R., Thein A. et al. Role of prophylactic uterine artery balloon catheters in the management of women with suspected placenta accreta. Int J Obstet Anesth. 2011;20(4):282–287. DOI: 10.1016/j.ijoa.2011.06.006.
53. Oyelese Y., Smulian J.C. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol. 2006;107(4):927–941. DOI: 10.1097/01.AOG.0000207559.15715.98.
54. Wong H.S., Hutton J., Zuccollo J. et al. The maternal outcome in placenta accreta: the significance of antenatal diagnosis and non-separation of placenta at delivery. N Z Med J. 2008;121(1277):30–38. PMID: 18677328.
55. Pri-Paz S., Fuchs K.M., Gaddipati S. et al. Comparison between emergent and elective delivery in women with placenta accreta. J Matern Fetal Neonatal Med. 2013;26(10):1007–1011. DOI: 10.3109/14767058.2013.766711.
56. Collins S.L., Alemdar B., van Beekhuizen H.J. et al. Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019;220(6):511–526. DOI: 10.1016/j.ajog.2019.02.054.
57. Erfani H., Salmanian B., Fox K.A. et al. Urologic morbidity associated with placenta accreta spectrum surgeries: single-center experience with a multidisciplinary team. Am J Obstet Gynecol. 2022;226(2):245.e1–245.e5. DOI: 10.1016/j.ajog.2021.08.010.
58. Lilker S.J., Meyer R.A., Downey K.N., Macarthur A.J. Anesthetic considerations for placenta accreta. Int J Obstet Anesth. 2011;20(4):288–292. DOI: 10.1016/j.ijoa.2011.06.001.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
